Page 360 - Read Online

Nounou. J Cancer Metastasis Treat 2018;4:29 I http://dx.doi.org/10.20517/2394-4722.2018.18 Page 3 of 3

researched for ease of scale-up and proper bench-to-bedside transformation. Consequently, a current focus
is on simple bioconjugate structures, which can be easily synthesized with high yield, reduced cost and high
stability profile of the final formulation. This could provide a practical direction for the development of novel
management tools and therapeutics, paving the road to affordable, scalable, stable, efficient and safe disease-
management strategies.

DECLARATIONS
Authors’ contributions
Nounou MI conceived the presented idea, developed the theoretical formalism and fully contributed to the
writing of the manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declares that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Muggia FM. Doxil in breast cancer. J Clin Oncol 1998;16:811-2.
2. Porche DJ. Liposomal doxorubicin (doxil). J Assoc Nurses AIDS Care 1996;7:55-9.
3. Tagami T, Ozeki T. Recent trends in clinical trials related to carrier-based drugs. J Pharm Sci 2017;106:2219-26.
4. Cagel M, Tesan FC, Bernabeu E, Salgueiro MJ, Zubillaga MB, Moretton MA, Chiappetta DA. Polymeric mixed micelles as
nanomedicines: achievements and perspectives. Eur J Pharm Biopharm 2017;113:211-28.
5. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control
Release 2012;161:175-87.
6. Hermanson GT. Bioconjugate Techniques, 3rd Edition. Academic Press; 2013.
7. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701.